United Therapeutics (UTHR) Upgraded to Neutral at Credit Suisse Group

Credit Suisse Group upgraded shares of United Therapeutics (NASDAQ:UTHR) from an underperform rating to a neutral rating in a research report sent to investors on Thursday morning, Benzinga reports. They currently have $98.00 target price on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. TheStreet upgraded shares of United Therapeutics from a c+ rating to a b- rating in a research report on Monday, February 11th. Oppenheimer set a $160.00 price objective on shares of United Therapeutics and gave the stock a buy rating in a research report on Tuesday, March 26th. BidaskClub upgraded shares of United Therapeutics from a hold rating to a buy rating in a research report on Friday, March 22nd. Wedbush set a $269.00 price objective on shares of United Therapeutics and gave the stock a buy rating in a research report on Monday, April 8th. Finally, LADENBURG THALM/SH SH set a $124.00 price objective on shares of United Therapeutics and gave the stock a hold rating in a research report on Thursday, February 28th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and three have assigned a buy rating to the company. United Therapeutics has a consensus rating of Hold and a consensus price target of $132.89.

UTHR opened at $94.64 on Thursday. The company has a quick ratio of 6.84, a current ratio of 7.19 and a debt-to-equity ratio of 0.45. United Therapeutics has a 1 year low of $93.27 and a 1 year high of $130.00. The firm has a market capitalization of $4.24 billion, a P/E ratio of 7.07 and a beta of 1.01.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($13.96). The firm had revenue of $362.70 million during the quarter, compared to analyst estimates of $335.72 million. United Therapeutics had a negative net margin of 9.36% and a negative return on equity of 5.78%. The business’s revenue for the quarter was down 6.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.76 earnings per share. As a group, equities research analysts forecast that United Therapeutics will post -5.03 earnings per share for the current fiscal year.

In other news, Director Christopher Patusky sold 3,370 shares of the company’s stock in a transaction on Thursday, March 7th. The shares were sold at an average price of $110.75, for a total transaction of $373,227.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. purchased a new stake in shares of United Therapeutics in the first quarter valued at about $29,000. Captrust Financial Advisors grew its holdings in shares of United Therapeutics by 384.9% in the fourth quarter. Captrust Financial Advisors now owns 257 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 204 shares during the period. First Mercantile Trust Co. grew its holdings in shares of United Therapeutics by 47.8% in the fourth quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 110 shares during the period. Financial Gravity Companies Inc. purchased a new stake in shares of United Therapeutics in the fourth quarter valued at about $44,000. Finally, Financial Gravity Wealth Inc. purchased a new stake in shares of United Therapeutics in the first quarter valued at about $46,000. 97.65% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Further Reading: Calculating net profit and net profit margin ratio

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.